CIBMTR Reporting Implementation Guide
0.1.6 - Trial Use 1
CIBMTR Reporting Implementation Guide - Local Development build (v0.1.6). See the Directory of published versions
Official URL: http://fhir.nmdp.org/ig/cibmtr-reporting/ValueSet/med-prior-exposure-vs | Version: 0.1.6 | |||
Active as of 2023-05-05 | Computable Name: RxNormPriorExposureVS |
Prior Exposure: Potential Study Eligibility
References
http://www.nlm.nih.gov/research/umls/rxnorm
Code | Display |
10473 | thiotepa |
1156487 | thiotepa Injectable Product |
1185673 | Mylotarg Injectable Product |
1294580 | gemtuzumab ozogamicin |
1294581 | gemtuzumab ozogamicin 1 MG/ML |
1294582 | gemtuzumab ozogamicin Injectable Product |
1294583 | gemtuzumab ozogamicin Injectable Solution |
1294584 | gemtuzumab ozogamicin 1 MG/ML Injectable Solution |
1366537 | Tepadina |
1597258 | blinatumomab |
1597260 | blinatumomab Injectable Product |
1597262 | blinatumomab 0.035 MG Injection |
1597263 | Blincyto |
1597266 | Blincyto Injectable Product |
1597267 | blinatumomab 0.035 MG Injection [Blincyto] |
1651249 | blinatumomab 0.035 MG |
1651250 | blinatumomab Injection |
1651252 | blinatumomab 0.035 MG [Blincyto] |
1651253 | blinatumomab Injection [Blincyto] |
1660002 | thiotepa 100 MG |
1660003 | thiotepa Injection |
1660004 | thiotepa 100 MG Injection |
1660008 | thiotepa 15 MG |
1660009 | thiotepa 15 MG Injection |
1919206 | thiotepa 100 MG [Tepadina] |
1919207 | thiotepa Injection [Tepadina] |
1919208 | Tepadina Injectable Product |
1919209 | thiotepa 100 MG Injection [Tepadina] |
1919210 | thiotepa 15 MG [Tepadina] |
1919211 | thiotepa 15 MG Injection [Tepadina] |
1942950 | inotuzumab ozogamicin |
1942951 | inotuzumab ozogamicin 0.9 MG |
1942952 | inotuzumab ozogamicin Injectable Product |
1942953 | inotuzumab ozogamicin Injection |
1942954 | inotuzumab ozogamicin 0.9 MG Injection |
1942955 | Besponsa |
1942956 | inotuzumab ozogamicin 0.9 MG [Besponsa] |
1942957 | inotuzumab ozogamicin Injection [Besponsa] |
1942958 | Besponsa Injectable Product |
1942959 | inotuzumab ozogamicin 0.9 MG Injection [Besponsa] |
1944699 | gemtuzumab ozogamicin 4.5 MG |
1944700 | gemtuzumab ozogamicin Injection |
1944701 | gemtuzumab ozogamicin 4.5 MG Injection |
1944702 | gemtuzumab ozogamicin 4.5 MG [Mylotarg] |
1944703 | gemtuzumab ozogamicin Injection [Mylotarg] |
1944704 | gemtuzumab ozogamicin 4.5 MG Injection [Mylotarg] |
2054068 | mogamulizumab |
2054077 | mogamulizumab-kpkc |
2054078 | mogamulizumab-kpkc 4 MG/ML |
2054079 | mogamulizumab Injectable Product |
2054080 | mogamulizumab Injection |
2054081 | 5 ML mogamulizumab-kpkc 4 MG/ML Injection |
2054082 | Poteligeo |
2054083 | mogamulizumab-kpkc 4 MG/ML [Poteligeo] |
2054084 | mogamulizumab Injection [Poteligeo] |
2054085 | Poteligeo Injectable Product |
2054086 | 5 ML mogamulizumab-kpkc 4 MG/ML Injection [Poteligeo] |
261585 | Mylotarg |
This value set contains 58 concepts
Expansion based on RxNorm version ??
Explanation of the columns that may appear on this page:
Level | A few code lists that FHIR defines are hierarchical - each code is assigned a level. In this scheme, some codes are under other codes, and imply that the code they are under also applies |
System | The source of the definition of the code (when the value set draws in codes defined elsewhere) |
Code | The code (used as the code in the resource instance) |
Display | The display (used in the display element of a Coding). If there is no display, implementers should not simply display the code, but map the concept into their application |
Definition | An explanation of the meaning of the concept |
Comments | Additional notes about how to use the code |